Delivery Order SPE2DR25D3101-SPE2DR26F5S87
- Not listed
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a $26,327.14 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on December 10, 2025, with a completion date of December 11, 2025. This contract represents a firm fixed-price delivery order under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor supporting federal medical procurement needs, particularly for military and...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order valued at $4,775.88 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on December 5, 2025, with an ultimate completion date of December 8, 2025. This firm fixed price delivery order represents a non-competitive set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,741.75 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of November 19, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,510.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL pharmaceutical supplies on September 3, 2025, with completion targeted for September 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,174.48 delivery order to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mls pharmaceutical supplies on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $2,473.70 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on December 9, 2025, with completion scheduled for December 10, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- SPE2DR25D3101Indefinite Delivery Contract
- SPE2DR25D3101-SPE2DR26F5S87Delivery Order
The Defense Logistics Agency awarded a $3,057.54 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on December 12, 2025, with an ultimate completion date of December 15, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical supplier to federal military and veteran healthcare systems. As a prime vendor under the DLA's comprehensive pharmaceutical support vehicle, the company supplies an extensive portfolio of medications and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for HUMIRA, a biologic immunosuppressant medication, reflects the company's ongoing role in fulfilling specialized pharmaceutical requirements for Department of Defense healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 12/11/25 |